Immunogenicity and growth inhibitory efficacy of the prime-boost immunization regime with DNA followed by recombinant vaccinia virus carrying the P29 gene of Babesia gibsoni in dogs

Experimental Parasitology

Volumn 123, Issue 4, 2009, Pages 296-301

  Fukumoto, Shinya ^a   Tamaki, Yoh ^a   Igarashi, Ikuo ^a   Suzuki, Hiroshi ^a   Xuan, Xuenan ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

Babesia gibsoni; DNA; Heterologous immunization; Vaccinia virus

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G2; LIPOPROTEIN; PLASMID DNA; PROTEIN P29; UNCLASSIFIED DRUG; VACCINIA VIRUS VECTOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BABESIA; BABESIA GIBSONI; CONTROLLED STUDY; DOG; FEMALE; GENE; IMMUNIZATION; INOCULATION; NONHUMAN; PARASITEMIA; PARASITOSIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, PROTOZOAN; BABESIA; BABESIOSIS; BLOTTING, WESTERN; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETIC VECTORS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; PLASMIDS; PROTOZOAN VACCINES; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSFECTION; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

BABESIA GIBSONI; CANIS FAMILIARIS; VACCINIA VIRUS;

EID: 70349973828     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.08.012     Document Type: Article

References (30)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
2. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., and Small Jr. P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. The Journal of Virology 70 (1996) 6418-6424
3. Bennink J.R., Yewdell J.W., Smith G.L., Moller C., and Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311 (1984) 578-579
4. Boozer A.L., and Macintire D.K. Canine babesiosis. Veterinary Clinics of North America: Small Animal Practice 33 (2003) 885-904 (viii)
5. Bout D.T., Mevelec M.N., Velge-Roussel F., Dimier-Poisson I., and Lebrun M. Prospects for a human Toxoplasma vaccine. Current Drug Targets-Immune, Endocrine & Metabolic Disorders 2 (2002) 227-234
6. Brown W.C., and Palmer G.H. Designing blood-stage vaccines against Babesia bovis and B. Bigemina. Parasitology Today 15 (1999) 275-281
7. Carson C., Antoniou M., Ruiz-Arguello M.B., Alcami A., Christodoulou V., Messaritakis I., Blackwell J.M., and Courtenay O. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 27 (2009) 1080-1086
8. Dunachie S.J., and Hill A.V. Prime-boost strategies for malaria vaccine development. The Journal of Experimental Biology 206 (2003) 3771-3779
9. Fukumoto S., Suzuki H., Igarashi I., and Xuan X. Fatal experimental transplacental Babesia gibsoni infections in dogs. International Journal for Parasitology 35 (2005) 1031-1035
10. Fukumoto S., Tamaki Y., Okamura M., Bannai H., Yokoyama N., Suzuki T., Igarashi I., Suzuki H., and Xuan X. Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs. Vaccine 25 (2007) 1334-1341
11. Fukumoto S., Tamaki Y., Shirafuji H., Harakawa S., Suzuki H., and Xuan X. Immunization with recombinant surface antigen P50 of Babesia gibsoni expressed in insect cells induced parasite growth inhibition in dogs. Clinical and Diagnostic Laboratory Immunology 12 (2005) 557-559
12. Fukumoto S., Xuan X., Igarashi I., Zhang S., Mugisha J., Ogata T., Nagasawa H., Fujisaki K., Suzuki N., and Mikami T. Morphological changes of Babesia gibsoni grown in canine red blood cell-substituted severe combined immune deficiency mice. Journal of Parasitology 86 (2000) 956-958
13. Fukumoto S., Xuan X., Inoue N., Igarashi I., Sugimoto C., Fujisaki K., Nagasawa H., Mikami T., and Suzuki H. Molecular characterization of a gene encoding a 29-kDa cytoplasmic protein of Babesia gibsoni and evaluation of its diagnostic potentiality. Molecular and Biochemical Parasitology 131 (2003) 129-136
14. Fukumoto S., Xuan X., Nishikawa Y., Inoue N., Igarashi I., Nagasawa H., Fujisaki K., and Mikami T. Identification and expression of a 50-kilodalton surface antigen of Babesia gibsoni and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 39 (2001) 2603-2609
15. Gilbert S.C., Schneider J., Hannan C.M., Hu J.T., Plebanski M., Sinden R., and Hill A.V. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20 (2002) 1039-1045
16. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., Hill A.V., Smith G.L., and McMichael A. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16 (1998) 439-445
17. Ishimine T., Makimura S., Kitazawa S., Tamura S., and Suzuki N. Pathophysiological findings on blood of Beagles experimentally infected with Babesia gibsoni. Japanese Journal of Tropical Medicine and Hygiene 6 (1978) 15-26
18. Kumar S., Epstein J.E., Richie T.L., Nkrumah F.K., Soisson L., Carucci D.J., and Hoffman S.L. A multilateral effort to develop DNA vaccines against falciparum malaria. Trends in Parasitology 18 (2002) 129-135
19. MacWilliams P.S. Erythrocytic rickettsia and protozoa of the dog and cat. Veterinary Clinics of North America: Small Animal Practice 17 (1987) 1443-1461
20. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine 9 (2003) 729-735
21. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
22. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., Lucientes J., Castillo J.A., and Larraga V. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 (2003) 2474-2484
23. Ramos I., Alonso A., Marcen J.M., Peris A., Castillo J.A., Colmenares M., and Larraga V. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26 (2008) 333-344
24. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., Culp J., Burkholder J.K., Swain W.F., Dixon R.M., Widera G., Vessey R., King A., Ogg G., Gallimore A., Haynes J.R., and Heydenburg Fuller D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 (2000) 764-778
25. Schneider J., Gilbert S.C., Hannan C.M., Degano P., Prieur E., Sheu E.G., Plebanski M., and Hill A.V. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunological Reviews 170 (1999) 29-38
26. Schneider J., Langermans J.A., Gilbert S.C., Blanchard T.J., Twigg S., Naitza S., Hannan C.M., Aidoo M., Crisanti A., Robson K.J., Smith G.L., Hill A.V., and Thomas A.W. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19 (2001) 4595-4602
27. Swain W.E., Heydenburg Fuller D., Wu M.S., Barr L.J., Fuller J.T., Culp J., Burkholder J., Dixon R.M., Widera G., Vessey R., and Roy M.J. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B. Developments in Biologicals 104 (2000) 115-119
28. Tokui M., Takei I., Tashiro F., Shimada A., Kasuga A., Ishii M., Ishii T., Takatsu K., Saruta T., and Miyazaki J. Intramuscular injection of expression plasmid DNA is an effective means of long-term systemic delivery of interleukin-5. Biochemical and Biophysical Research Communications 233 (1997) 527-531
29. Tsuji M., and Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends in Parasitology 19 (2003) 88-93
30. Yasuda A., Kimura-Kuroda J., Ogimoto M., Miyamoto M., Sata T., Sato T., Takamura C., Kurata T., Kojima A., and Yasui K. Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus. The Journal of Virology 64 (1990) 2788-2795